Jan 8 (Reuters) -
ALESTA THERAPEUTICS RAISES €65 MILLION SERIES A FINANCING TO ADVANCE ORAL SMALL MOLECULES FOR RARE DISEASES
ALESTA THERAPEUTICS: LEAD PROGRAM, ALE1, BEING DEVELOPED IN HYPOPHOSPHATASIA WITH PLANS TO ENTER CLINICAL DEVELOPMENT IN 2025
Source text: ID:nPn81S4KPa
Further company coverage: [ ]
((Reuters.Brief@thomsonreuters.com))